Hyperosmolar Stress Upregulates HLA-DR Expression in Human Conjunctival Epithelium in Dry Eye Patients and in Vitro Models
Overview
Affiliations
Purpose: To investigate the immune response of human conjunctival epithelium to hyperosmolar stress.
Methods: Tear osmolarity was measured in 15 normal subjects and 25 dry eye (DE) patients; conjunctival imprint cytology samples were obtained at the nasal bulbar area. Subconfluent primary human conjunctival epithelial cells (pHCECs) and human conjunctival organ cultures (hCOCs), both cultured in iso-osmolar medium (305 mOsm/L), were exposed for 24 hours to media with progressively higher osmolarity, with or without the ion channel inhibitor ruthenium red (RuR). Human leukocyte antigen (HLA)-DR expression was evaluated by immunocytochemistry, on imprints from subjects, on primary human conjunctival epithelial cells, on formalin fixed-paraffin embedded hCOCs, and by RT-PCR. Statistical evaluation was performed by applying the unpaired Student's t test, as well as Spearman's rho and Pearson's r correlation coefficients (significance P < 0.05).
Results: HLA-DR expression increased in DE subjects with respect to control (% mean ± SD, respectively, 46.16 ± 7.2 vs. 7.48 ± 1.14, P < 0.0001) and exhibited significantly high correlations with tear osmolarity values (r = 0.614; P < 0.0001). In vitro experiments showed a progressive increase in HLA-DR expression as the osmolarity of the medium was increased from 6.75 ± 1.16 (% mean ± SD) in iso-osmolar-cultured cells to 9.96 ± 1.37 and 12.94 ± 4.04 in cells cultured in, respectively, 350 and 400 mOsm/L (P < 0.05). A stepwise progressive increase was also found in hCOCs. Results were confirmed by RT-PCR. Ruthenium red significantly reduced HLA-DR expression in hyperosmolar-cultured cells.
Conclusions: Data from complementary techniques demonstrate that extracellular hyperosmolarity induces HLA-DR overexpression in human conjunctival epithelial cells in both DE patients and in vitro cell culture models.
NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease.
Zhuang D, Misra S, Mugisho O, Rupenthal I, Craig J Int J Mol Sci. 2023; 24(13).
PMID: 37446038 PMC: 10341612. DOI: 10.3390/ijms241310866.
Lee H, Yang S, Cheon E, Shin S, Byun Y, Kim H Mol Vis. 2022; 28:114-123.
PMID: 36034736 PMC: 9352363.
Mucosal immunology of the ocular surface.
de Paiva C, St Leger A, Caspi R Mucosal Immunol. 2022; 15(6):1143-1157.
PMID: 36002743 PMC: 9400566. DOI: 10.1038/s41385-022-00551-6.
Astolfi G, Lorenzini L, Gobbo F, Sarli G, Versura P J Clin Med. 2022; 11(6).
PMID: 35329844 PMC: 8948919. DOI: 10.3390/jcm11061518.
Srinivasan S, Manoj V Clin Ophthalmol. 2021; 15:2421-2435.
PMID: 34135570 PMC: 8200152. DOI: 10.2147/OPTH.S294427.